About this trial
This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease.
Eligibility criteria
Qualifiers
Individuals ≥ 60 years old at the time of screening (calculated from the date of birth to the date of screening)
New onset or increase from baseline of: nasal congestion, rhinorrhea, sore throat, hoarseness, cough, sputum production, dyspnea, wheezing, hypoxemia, or
Admitting diagnosis suggestive of ARI (e.g., pneumonia, upper respiratory infection, bronchitis, influenza, cough, viral respiratory illness, respiratory distress, or respiratory failure), or
Admitting diagnosis was the exacerbation of an underlying cardiac or pulmonary disease involving acute respiratory symptoms within the previous 2 weeks (e.g., congestive heart failure [CHF], chronic obstructive pulmonary disease [COPD], or asthma exacerbation).
Disqualifiers
Symptom onset > 6 days prior to screening date
Acute symptoms confirmed to be unrelated to infection or as assessed by the investigator
Admission to any hospital within the 30 days preceding the screening date
Previously enrolled in the study in the last 45 days
Trial design
Treatments tested in this trial
- Not listed